{
    "root": "2b49645c-34d0-c6ab-e063-6394a90aaee5",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Levetiracetam",
        "suffix": {
            "text": "Levetiracetam"
        }
    },
    "value": "20250109",
    "ingredients": [
        {
            "name": "ACESULFAME POTASSIUM",
            "code": "23OV73Q5G9"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "GLYCYRRHIZIN",
            "code": "6FO62043WK"
        },
        {
            "name": "MALTITOL",
            "code": "D65DG142WK"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SODIUM CITRATE",
            "code": "1Q73Q2JULR"
        },
        {
            "name": "LEVETIRACETAM",
            "code": "44YRR34555"
        }
    ],
    "indications": "levetiracetam oral solution indicated adjunctive therapy treatment : partial onset seizures patients one month age older epilepsy ( 1.1 ) myoclonic seizures patients 12 years age older juvenile myoclonic epilepsy ( 1.2 ) primary generalized tonic-clonic seizures patients 6 years age older idiopathic generalized epilepsy ( 1.3 )",
    "contraindications": "\u2022 oral solution pediatric patients body weight \u2264 20 kg ( 2.1 ) . \u2022 pediatric patients , weight-based dosing oral solution calibrated measuring device ( household teaspoon tablespoon ) ( 2.1 ) . partial onset seizures \u2022 1 month < 6 months : 7 mg/kg twice daily ; increase 7 mg/kg twice daily every 2 weeks recommended dose 21 mg/kg twice daily ( 2.2 ) \u2022 6 months < 4 years : 10 mg/kg twice daily ; increase 10 mg/kg twice daily every 2 weeks recommended dose 25 mg/kg twice daily ( 2.2 ) \u2022 4 years < 16 years : 10 mg/kg twice daily ; increase 10 mg/kg twice daily every 2 weeks recommended dose 30 mg/kg twice daily ( 2.2 ) \u2022 adults 16 years older : 500 mg twice daily ; increase 500 mg twice daily every 2 weeks recommended dose 1,500 mg twice daily ( 2.2 ) myoclonic seizures adults pediatric patients 12 years older \u2022 500 mg twice daily ; increase 500 mg twice daily every 2 weeks recommended dose 1,500 mg twice daily ( 2.3 ) primary generalized tonic-clonic seizures \u2022 6 years < 16 years : 10 mg/kg twice daily , increase increments 10 mg/kg twice daily every 2 weeks recommended dose 30 mg/kg twice daily ( 2.4 ) \u2022 adults 16 years older : 500 mg twice daily , increase 500 mg twice daily every 2 weeks recommended dose 1,500 mg twice daily ( 2.4 ) adult patients impaired renal function \u2022 dose adjustment recommended , based patient \u2019 estimated creatinine clearance ( 2.5 , 8.6 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "levetiracetam oral solution patients hypersensitivity levetiracetam . included anaphylaxis angioedema levetiracetam oral solution contraindicated patients hypersensitivity levetiracetam . included anaphylaxis angioedema [ ( 5.4 ) ] .",
    "indications_original": "Levetiracetam oral solution is indicated for adjunctive therapy in the treatment of: Partial onset seizures in patients\u00a0one month\u00a0of age and older with epilepsy ( 1.1 ) Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy ( 1.2 ) Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy ( 1.3 )",
    "contraindications_original": "\u2022\u00a0Use the oral solution for pediatric patients with body weight \u2264 20 kg ( 2.1 ). \u2022\u00a0For pediatric patients, use weight-based dosing for the oral solution with a calibrated measuring device (not a household teaspoon or tablespoon) ( 2.1 ). Partial Onset Seizures \u2022 1 Month to < 6 Months: 7 mg/kg twice daily; increase by 7 mg/kg twice\u00a0 daily every 2 weeks to recommended dose of 21 mg/kg twice daily ( 2.2 ) \u2022\u00a06 Months to < 4 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily ( 2.2 ) \u2022 4 Years to < 16 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily ( 2.2 ) \u2022 Adults 16 Years and Older: 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to a recommended dose of 1,500 mg twice daily ( 2.2 ) Myoclonic Seizures in Adults and Pediatric Patients 12 Years and Older \u2022 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to recommended dose of 1,500 mg twice daily ( 2.3 ) Primary Generalized Tonic-Clonic Seizures \u2022 6 Years to < 16 Years: 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily ( 2.4 ) \u2022 Adults 16 Years and Older: 500 mg twice daily, increase by 500 mg twice daily every 2 weeks to recommended dose of 1,500 mg twice daily ( 2.4 ) Adult Patients with Impaired Renal Function \u2022 Dose adjustment is recommended, based on the patient\u2019s estimated creatinine clearance ( 2.5 , 8.6 )",
    "adverseReactions_original": "Levetiracetam oral solution is\n       in patients with a hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema \n       Levetiracetam oral solution is\n        contraindicated in patients with a hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema \n       \n \n   [see Warnings and Precautions (\n        \n  \n    5.4)]."
}